What are the alternative treatments to Paxlovid (nirmatrelvir/ritonavir) for patients who cannot receive it due to drug‑drug interactions, severe renal or hepatic impairment, or pregnancy?

Paxlovid Alternatives for COVID-19 Treatment

Molnupiravir is the primary alternative to Paxlovid for patients who cannot receive nirmatrelvir/ritonavir due to drug-drug interactions, severe renal impairment (eGFR <30 mL/min), or severe hepatic impairment (Child-Pugh Class C). 1

Primary Alternative: Molnupiravir

The American College of Physicians 2024 guidelines explicitly support molnupiravir as an alternative oral antiviral for symptomatic patients with confirmed mild to moderate COVID-19 who are within 5 days of symptom onset and at high risk for progression to severe disease 1. Evidence demonstrates that molnupiravir reduces all-cause mortality and COVID-19 hospital admissions compared to no treatment, with no difference in serious adverse events 1.

Key Advantages of Molnupiravir:

• No significant drug-drug interactions (unlike Paxlovid's extensive CYP3A interactions) 2, 3
• No dose adjustment required for renal or hepatic impairment 4
• Can be used when Paxlovid is contraindicated

Critical Limitations:

• Contraindicated in pregnancy due to potential mutagenic effects 3
• Not for use in children or adolescents due to concerns about bone and cartilage toxicity 3
• Requires reliable contraception in persons of childbearing potential 3
• Lower efficacy than Paxlovid: 30% relative risk reduction versus 88% for nirmatrelvir/ritonavir 3

When Paxlovid Cannot Be Used

Drug-Drug Interactions

Paxlovid contains ritonavir, a potent CYP3A inhibitor that causes potentially severe, life-threatening, or fatal drug interactions 5, 6. The FDA label carries a boxed warning about these interactions. Common contraindicated medications include certain sedatives (estazolam), antipsychotics (quetiapine), and antiplatelet agents (clopidogrel) 7.

In these cases, switch to molnupiravir 8, 2.

Severe Renal Impairment

• eGFR <30 mL/min: While recent 2026 data shows Paxlovid can be used with modified dosing (300/100 mg day 1, then 150/100 mg once daily days 2-5) in severe renal impairment including hemodialysis 6, 9, molnupiravir remains the simpler alternative requiring no dose adjustment 4
• Hemodialysis patients: If using Paxlovid, administer after dialysis 6

Severe Hepatic Impairment

Paxlovid is not recommended in Child-Pugh Class C hepatic impairment 5, 6. Molnupiravir requires no dose adjustment and is the preferred alternative 4.

Pregnancy

The FDA label does not explicitly contraindicate Paxlovid in pregnancy, but data are limited 5, 6. Molnupiravir is contraindicated in pregnancy due to mutagenic concerns 3. In pregnant patients who cannot receive Paxlovid, remdesivir (intravenous) may be considered if hospitalization is warranted, though the remdesivir guidelines exclude pregnant women from their evidence base 10.

Alternative Consideration: Remdesivir

For hospitalized patients or those requiring facility-based care, remdesivir (intravenous) is an option 10. However, this requires:

• IV administration in hospital or acute care-equivalent facility
• 5-day course (200 mg day 1, then 100 mg daily)
• Not suitable for outpatient management
• Excluded in severe renal impairment (eGFR <30 mL/min) per FDA recommendations 10

What NOT to Use

The 2024 ACP guidelines explicitly state:

• Do NOT use ivermectin for COVID-19 treatment 1
• Do NOT use sotrovimab (monoclonal antibody no longer effective against current variants) 1

Clinical Algorithm for Paxlovid Alternatives

1. First, attempt Paxlovid if no contraindications (most effective: 88% risk reduction) 3

2. If drug-drug interactions present:

   • Review if medications can be temporarily held or adjusted
   • If not manageable → Use molnupiravir

3. If severe renal impairment (eGFR <30):

   • Consider modified Paxlovid dosing (newer 2026 data supports this) 6, 9
   • Or use molnupiravir (simpler, no adjustment needed)

4. If severe hepatic impairment (Child-Pugh C):

   • Use molnupiravir (only option)

5. If pregnant or childbearing potential:

   • Paxlovid may be considered (limited data)
   • Do NOT use molnupiravir
   • Consider remdesivir if hospitalization indicated

6. If pediatric (<18 years):

   • Paxlovid approved ≥12 years and ≥40 kg 5
   • Do NOT use molnupiravir

Common Pitfalls

• Starting treatment too late: All oral antivirals must be initiated within 5 days of symptom onset 1, 5, 6
• Overlooking drug interactions: Always review complete medication list before prescribing Paxlovid 5, 6
• Using molnupiravir in pregnancy: Absolute contraindication 3
• Assuming molnupiravir equals Paxlovid efficacy: Molnupiravir is significantly less effective (30% vs 88% risk reduction) 3